Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
This open-label, multicentre, phase 2 trial evaluated the efficacy and tolerability of the mammalian target of rapamycin inhibitor ridaforolimus in women with advanced endometrial cancer.
